Magnetar Financial LLC reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 36.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,335 shares of the life sciences company’s stock after selling 5,393 shares during the period. Magnetar Financial LLC’s holdings in Illumina were worth $1,860,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. Paradigm Asset Management Co. LLC increased its stake in Illumina by 5.6% during the 2nd quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after buying an additional 50 shares in the last quarter. Patriot Financial Group Insurance Agency LLC increased its stake in Illumina by 1.4% during the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 3,126 shares of the life sciences company’s stock worth $528,000 after buying an additional 43 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its stake in Illumina by 298.7% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 10,447 shares of the life sciences company’s stock worth $1,813,000 after buying an additional 7,827 shares in the last quarter. Eagle Asset Management Inc. purchased a new stake in Illumina during the 2nd quarter worth approximately $27,175,000. Finally, Intellectus Partners LLC boosted its holdings in shares of Illumina by 6.6% during the 2nd quarter. Intellectus Partners LLC now owns 10,783 shares of the life sciences company’s stock worth $1,871,000 after purchasing an additional 664 shares during the last quarter. Institutional investors own 91.75% of the company’s stock.
ILMN has been the topic of several recent research reports. Citigroup boosted their target price on Illumina from $180.00 to $220.00 and gave the stock a “neutral” rating in a report on Wednesday, October 25th. Robert W. Baird upgraded Illumina from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $184.00 to $228.00 in a report on Wednesday, October 25th. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $229.00 target price on the stock in a report on Friday, October 27th. Barclays boosted their target price on Illumina from $150.00 to $185.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 25th. Finally, BidaskClub cut Illumina from a “buy” rating to a “hold” rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the stock. Illumina currently has a consensus rating of “Buy” and an average price target of $201.98.
Shares of Illumina, Inc. (NASDAQ:ILMN) opened at $214.67 on Friday. Illumina, Inc. has a 12-month low of $120.00 and a 12-month high of $230.72. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22. The firm has a market capitalization of $31,510.00, a price-to-earnings ratio of 61.71, a PEG ratio of 3.49 and a beta of 0.79.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The business had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. During the same quarter in the prior year, the company earned $0.97 earnings per share. The company’s revenue was up 17.6% on a year-over-year basis. research analysts forecast that Illumina, Inc. will post 3.75 EPS for the current fiscal year.
In related news, SVP Oene Mark Van sold 9,729 shares of the stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $211.33, for a total value of $2,056,029.57. Following the transaction, the senior vice president now owns 24,908 shares of the company’s stock, valued at $5,263,807.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jay T. Flatley sold 20,000 shares of the stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $211.11, for a total value of $4,222,200.00. Following the completion of the transaction, the director now directly owns 539,176 shares in the company, valued at approximately $113,825,445.36. The disclosure for this sale can be found here. Insiders have sold 166,150 shares of company stock worth $34,767,331 in the last ninety days. Corporate insiders own 0.89% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.dispatchtribunal.com/2017/12/08/magnetar-financial-llc-cuts-holdings-in-illumina-inc-ilmn.html.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.